Company news
Immutep Ltd (ASX:IMM) news
Immutep Ltd news releases on 6ix. Latest, Aug 25, 2016: European Patent Grants for IMP731 Antibody
Press releases — page 7
European Patent Grants for IMP731 Antibody
August 24, 2016
PRR Collaborates In New Clinical Trial For Imp321
July 12, 2016
First Data From Phase IIb Clinical Trial of Imp321
June 21, 2016
Prima BioMed Files U.S Shelf Registration Statement
May 29, 2016
PRR Enters Agreement with Sydys to Advance CVac Program
May 12, 2016
Japanese Patent Grants For IMP321 In Cancer
May 1, 2016
Appendix 4C - quarterly March 2016
April 8, 2016
Proposed Acquisition of Immutep
March 30, 2016
First patient dosed in AIPAC
March 2, 2016
US patent granted for IMP731 antibody
February 11, 2016
Prima initiates Phase I melanoma study in Australia
February 10, 2016